Figure 5.

Methylation in the CACNA2D3 CpG island in primary breast cancers treated adjuvantly with endocrine therapy is associated with increased risk of visceral metastasis. (A) Percentage methylation at CpG9 in non-relapsing and relapsing primary breast carcinomas. The figure shows percentage methylation, determined by pyrosequencing, in individual cases which remained disease free or which later relapsed at various distant organ sites. (B) Methylation in CACNA2D3 predicts visceral relapse in tamoxifen-treated primary breast carcinomas. The figure shows the percentage of cases with methylation in primary cancers that did not relapse (‘none’), in all relapsing cases (‘all’) and in the indicated metastatic sites. The P-value, calculated as described in Materials and Methods is shown above each column.